Cumberland Pharmaceuticals Inc.
CPIX
$4.35
-$1.01-18.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 28.64% | 0.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.24% | 14.86% | |||
| Cost of Revenue | -27.87% | 49.40% | |||
| Gross Profit | 21.61% | 8.97% | |||
| SG&A Expenses | -11.31% | 6.73% | |||
| Depreciation & Amortization | -31.12% | 35.34% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.12% | 13.89% | |||
| Operating Income | 170.14% | -8.71% | |||
| Income Before Tax | 164.02% | -28.39% | |||
| Income Tax Expenses | 110.00% | -600.00% | |||
| Earnings from Continuing Operations | 165.64% | -23.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 504.55% | 69.01% | |||
| Net Income | 166.03% | -23.30% | |||
| EBIT | 170.14% | -8.71% | |||
| EBITDA | 772.31% | 40.25% | |||
| EPS Basic | 161.70% | -24.02% | |||
| Normalized Basic EPS | 160.36% | -11.28% | |||
| EPS Diluted | 157.06% | -27.45% | |||
| Normalized Diluted EPS | 159.11% | -11.28% | |||
| Average Basic Shares Outstanding | 6.95% | -0.58% | |||
| Average Diluted Shares Outstanding | 9.22% | -0.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||